Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Connect Bio Reports Positive Phase I Data for Atopic Dermatitis Treatment

publication date: May 6, 2019

Connect Biopharma of Suzhou completed a successful Phase I single ascending dose trial of its novel IL-4Rα antibody, CBP-201. Connect is testing CBP-201 as a treatment for atopic dermatitis and other Th2 inflammatory diseases. The double-blind, placebo-controlled study, conducted in Melbourne, evaluated the safety, pharmacokinetics and pharmacodynamics of CBP-201 in 40 healthy adults. The company expects to post topline data from a Phase Ib CBP-201 trial, already underway, in late 2019. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here